Compugen Ltd. Daily Stock Analysis

Daily Stock Analysis, CGEN, Compugen Ltd, priceseries

Compugen Ltd. Daily Stock Analysis
Stock Information
Open
2.89
Close
2.96
High
3.04
Low
2.89
Previous Close
2.92
Daily Price Gain
0.04
YTD High
4.64
YTD High Date
Jan 4, 2022
YTD Low
2.54
YTD Low Date
Feb 24, 2022
YTD Price Change
-1.68
YTD Gain
-36.21%
52 Week High
9.61
52 Week High Date
Mar 16, 2021
52 Week Low
2.54
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-4.71
52 Week Gain
-61.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 18. 2017
4.30
May 31. 2017
4.76
8 Trading Days
10.63%
Link
LONG
Sep 15. 2017
3.40
Sep 28. 2017
3.71
9 Trading Days
9.11%
Link
LONG
Jan 17. 2018
2.75
Jan 31. 2018
3.00
10 Trading Days
9.18%
Link
LONG
Feb 13. 2018
2.90
Mar 20. 2018
4.17
24 Trading Days
43.78%
Link
LONG
Mar 29. 2018
4.45
Apr 2. 2018
4.72
1 Trading Days
6.18%
Link
LONG
May 25. 2018
3.35
Jun 18. 2018
3.70
15 Trading Days
10.51%
Link
LONG
Aug 15. 2018
3.20
Sep 6. 2018
3.71
15 Trading Days
15.95%
Link
LONG
Jan 4. 2019
2.52
Feb 4. 2019
3.45
20 Trading Days
37.06%
Link
LONG
Jun 5. 2019
3.15
Jul 2. 2019
3.67
19 Trading Days
16.48%
Link
LONG
Oct 23. 2019
4.17
Nov 11. 2019
4.97
13 Trading Days
19.18%
Link
LONG
Jan 23. 2020
6.51
Feb 24. 2020
9.15
21 Trading Days
40.50%
Link
LONG
Apr 3. 2020
7.45
May 1. 2020
13.95
19 Trading Days
87.30%
Link
Company Information
Stock Symbol
CGEN
Exchange
NasdaqGM
Company URL
http://www.cgen.com
Company Phone
011-972-3-765-8585
CEO
Anat Cohen-Dayag
Headquarters
-
Business Address
26 HAROKMIM STREET, BUILDING D, HOLON, ISRAEL 5885849
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001119774
About

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Description

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading